Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Mauritius has been steadily growing over the past few years.
Customer preferences: Patients in Mauritius suffering from cardiovascular diseases have been increasingly opting for anti-coagulants as a treatment option. This can be attributed to the convenience of taking anti-coagulants orally as opposed to injections, which was the standard mode of treatment in the past. Additionally, the availability of a wider variety of anti-coagulants in the market has given patients more options to choose from.
Trends in the market: One of the major trends in the Anti-Coagulants market in Mauritius is the shift towards direct oral anti-coagulants (DOACs). DOACs have gained popularity due to their ease of use and lower risk of bleeding compared to traditional anti-coagulants such as warfarin. This trend is expected to continue in the coming years as more DOACs are introduced into the market.Another trend in the market is the increasing focus on prevention rather than treatment. Healthcare providers in Mauritius have been placing greater emphasis on preventive measures such as lifestyle changes and early detection of cardiovascular diseases. This has led to a decrease in the number of patients requiring anti-coagulant treatment, but has also resulted in a more informed patient population that is more likely to opt for anti-coagulants as a preventive measure.
Local special circumstances: Mauritius has a high prevalence of cardiovascular diseases, which has contributed to the growth of the Anti-Coagulants market in the country. Additionally, the country has a relatively well-developed healthcare system that has been able to provide access to anti-coagulants to a large section of the population.
Underlying macroeconomic factors: The growth of the Anti-Coagulants market in Mauritius can be attributed to a combination of factors such as increasing healthcare expenditure, rising disposable incomes, and an aging population. The government has also been taking steps to improve healthcare infrastructure and increase access to healthcare services, which has contributed to the growth of the market. The increasing prevalence of lifestyle diseases such as obesity and diabetes has also led to an increase in the number of patients requiring anti-coagulant treatment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
